Immix Biopharma Overview
Latest ROE for Immix Biopharma: -41.47% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-41.47%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for IMMX is -41.47%. That is below the sector sector average of -4.03%. Investors often review this figure alongside Immix Biopharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, IMMX currently prints -41.47% for ROE, while the sector average sits near -4.03%. That is roughly 930.2% below the sector mean. Large gaps often invite a closer look at Immix Biopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Immix Biopharma converts resources into returns. At -41.47%, IMMX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IMMX's ROE (-41.47%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
